New insider Trimarchi Thomas claimed ownership of 394,856 shares (SEC Form 3)
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 07/23/2024 |
3. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 394,856 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (1) | 06/25/2029 | Common Stock | 115,000 | $17 | D | |
| Stock Option (Right to Buy) | (2) | 09/17/2030 | Common Stock | 16,419 | $42.19 | D | |
| Stock Option (Right to Buy) | (3) | 02/09/2031 | Common Stock | 22,145 | $68.87 | D | |
| Stock Option (Right to Buy) | (4) | 12/01/2031 | Common Stock | 158,127 | $40.03 | D | |
| Explanation of Responses: |
| 1. The stock option is fully vested and exercisable. The stock option vested in 48 monthly installments from June 26, 2019 to June 26, 2023. |
| 2. The stock option is fully vested and exercisable. The stock option vested as to 2,736 shares on October 18, 2020 and as to the remainder of the shares in 40 monthly installments thereafter through February 18, 2024. |
| 3. 18,915 of the shares subject to this option are vested and exercisable. The option vests in 48 equal monthly installments from February 10, 2021 to February 10, 2025, subject to the Reporting Person's continued service to the Issuer through each such date. |
| 4. 102,123 of the shares subject to this option are vested and exercisable. The option vested as to 25% of the shares on December 2, 2022 and as to the remainder of the shares in 36 monthly installments thereafter through December 2, 2025, subject to the Reporting Person's continued service to the Issuer through each such date. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Brian C. Stephenson, Attorney-in-Fact | 07/29/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||